Predictive factors and survival rate for brain metastasis from breast cancer

Ah Lee Jung, Won Bae Jeoung, Sang- Uk Woo, Jae Bok Lee, Whan Koo Byum

Research output: Contribution to journalArticle

Abstract

Purpose: The incidence of symptomatic brain metastases from breast cancerhas ranged from 10% to 16%. Brain metastases are traditionally viewed as a late complication of systemic disease, for which few effective treatment options exist. The aim of this study was to evaluate the factors that can predict brain metastases and to analyze the survival rate as compared with other systemic metastases. Methods: Between February 1983 and October 2005, 119 patient who developed systemic metastasis during the follow up period after optimal surgical treatment at Korea University Hospital were included in this study. Twenty-nine of these 119 patients had complaints of symptoms and they were consequently diagnosed as having brain metastases. Results: Estrogen receptor (-), progesterone receptor (-) and Her2 (-), and Triple negative were a significantly higher in the patients with brain metastases (p=0.04). The other clinicopathologic factors showed no difference between the patients with brain metastases and the patients without brain metastases. Lung metastases existed previously more often than the other systemic metastases (p=0.04). The overall survival of the patients with brain metastases was not significantly different from the patients with other systemic metastases. However, the disease specific survival of patients with brain metastases, as compared with other systemic metastases was poorer than that for patients with bone and lung metastases, respectively (p=0.01 and 0.03). A poor prognosis was shown for the cases with brain metastases within 1 yr after operation. Conclusion: Clinician should give attention to the possibility of brain metastases for the breast cancer patients with triple negative findings or the patients who have developed lung metastases as this represents a symptom of central nervous system.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalJournal of Breast Cancer
Volume11
Issue number2
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Survival Rate
Breast Neoplasms
Neoplasm Metastasis
Brain
Lung
Survival
Progesterone Receptors
Korea
Estrogen Receptors
Breast
Central Nervous System

Keywords

  • Brain metastases
  • Breast cancer
  • Predictive factor
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predictive factors and survival rate for brain metastasis from breast cancer. / Jung, Ah Lee; Jeoung, Won Bae; Woo, Sang- Uk; Lee, Jae Bok; Byum, Whan Koo.

In: Journal of Breast Cancer, Vol. 11, No. 2, 01.06.2008, p. 71-76.

Research output: Contribution to journalArticle

Jung, Ah Lee ; Jeoung, Won Bae ; Woo, Sang- Uk ; Lee, Jae Bok ; Byum, Whan Koo. / Predictive factors and survival rate for brain metastasis from breast cancer. In: Journal of Breast Cancer. 2008 ; Vol. 11, No. 2. pp. 71-76.
@article{d3cf5ae0f7bf4cb2a20492562f01d529,
title = "Predictive factors and survival rate for brain metastasis from breast cancer",
abstract = "Purpose: The incidence of symptomatic brain metastases from breast cancerhas ranged from 10{\%} to 16{\%}. Brain metastases are traditionally viewed as a late complication of systemic disease, for which few effective treatment options exist. The aim of this study was to evaluate the factors that can predict brain metastases and to analyze the survival rate as compared with other systemic metastases. Methods: Between February 1983 and October 2005, 119 patient who developed systemic metastasis during the follow up period after optimal surgical treatment at Korea University Hospital were included in this study. Twenty-nine of these 119 patients had complaints of symptoms and they were consequently diagnosed as having brain metastases. Results: Estrogen receptor (-), progesterone receptor (-) and Her2 (-), and Triple negative were a significantly higher in the patients with brain metastases (p=0.04). The other clinicopathologic factors showed no difference between the patients with brain metastases and the patients without brain metastases. Lung metastases existed previously more often than the other systemic metastases (p=0.04). The overall survival of the patients with brain metastases was not significantly different from the patients with other systemic metastases. However, the disease specific survival of patients with brain metastases, as compared with other systemic metastases was poorer than that for patients with bone and lung metastases, respectively (p=0.01 and 0.03). A poor prognosis was shown for the cases with brain metastases within 1 yr after operation. Conclusion: Clinician should give attention to the possibility of brain metastases for the breast cancer patients with triple negative findings or the patients who have developed lung metastases as this represents a symptom of central nervous system.",
keywords = "Brain metastases, Breast cancer, Predictive factor, Survival",
author = "Jung, {Ah Lee} and Jeoung, {Won Bae} and Woo, {Sang- Uk} and Lee, {Jae Bok} and Byum, {Whan Koo}",
year = "2008",
month = "6",
day = "1",
doi = "10.4048/jbc.2008.11.2.71",
language = "English",
volume = "11",
pages = "71--76",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "2",

}

TY - JOUR

T1 - Predictive factors and survival rate for brain metastasis from breast cancer

AU - Jung, Ah Lee

AU - Jeoung, Won Bae

AU - Woo, Sang- Uk

AU - Lee, Jae Bok

AU - Byum, Whan Koo

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: The incidence of symptomatic brain metastases from breast cancerhas ranged from 10% to 16%. Brain metastases are traditionally viewed as a late complication of systemic disease, for which few effective treatment options exist. The aim of this study was to evaluate the factors that can predict brain metastases and to analyze the survival rate as compared with other systemic metastases. Methods: Between February 1983 and October 2005, 119 patient who developed systemic metastasis during the follow up period after optimal surgical treatment at Korea University Hospital were included in this study. Twenty-nine of these 119 patients had complaints of symptoms and they were consequently diagnosed as having brain metastases. Results: Estrogen receptor (-), progesterone receptor (-) and Her2 (-), and Triple negative were a significantly higher in the patients with brain metastases (p=0.04). The other clinicopathologic factors showed no difference between the patients with brain metastases and the patients without brain metastases. Lung metastases existed previously more often than the other systemic metastases (p=0.04). The overall survival of the patients with brain metastases was not significantly different from the patients with other systemic metastases. However, the disease specific survival of patients with brain metastases, as compared with other systemic metastases was poorer than that for patients with bone and lung metastases, respectively (p=0.01 and 0.03). A poor prognosis was shown for the cases with brain metastases within 1 yr after operation. Conclusion: Clinician should give attention to the possibility of brain metastases for the breast cancer patients with triple negative findings or the patients who have developed lung metastases as this represents a symptom of central nervous system.

AB - Purpose: The incidence of symptomatic brain metastases from breast cancerhas ranged from 10% to 16%. Brain metastases are traditionally viewed as a late complication of systemic disease, for which few effective treatment options exist. The aim of this study was to evaluate the factors that can predict brain metastases and to analyze the survival rate as compared with other systemic metastases. Methods: Between February 1983 and October 2005, 119 patient who developed systemic metastasis during the follow up period after optimal surgical treatment at Korea University Hospital were included in this study. Twenty-nine of these 119 patients had complaints of symptoms and they were consequently diagnosed as having brain metastases. Results: Estrogen receptor (-), progesterone receptor (-) and Her2 (-), and Triple negative were a significantly higher in the patients with brain metastases (p=0.04). The other clinicopathologic factors showed no difference between the patients with brain metastases and the patients without brain metastases. Lung metastases existed previously more often than the other systemic metastases (p=0.04). The overall survival of the patients with brain metastases was not significantly different from the patients with other systemic metastases. However, the disease specific survival of patients with brain metastases, as compared with other systemic metastases was poorer than that for patients with bone and lung metastases, respectively (p=0.01 and 0.03). A poor prognosis was shown for the cases with brain metastases within 1 yr after operation. Conclusion: Clinician should give attention to the possibility of brain metastases for the breast cancer patients with triple negative findings or the patients who have developed lung metastases as this represents a symptom of central nervous system.

KW - Brain metastases

KW - Breast cancer

KW - Predictive factor

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=70350686230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350686230&partnerID=8YFLogxK

U2 - 10.4048/jbc.2008.11.2.71

DO - 10.4048/jbc.2008.11.2.71

M3 - Article

AN - SCOPUS:70350686230

VL - 11

SP - 71

EP - 76

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 2

ER -